ClinicalTrials.gg
TerminatedNCT01181921Updated May 1, 2014Results posted

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

A Phase 4 interventional study of Galantamine in Alzheimer Disease, sponsored by Janssen-Cilag, S.A.. Terminated at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-01.

Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Phase 4, Interventional, and Basic science

How we know

Why this study was terminated
The recruitment rate was very low (one screening failure and one early withdrawal patient)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing galantamine in Alzheimer Disease — none open to participants now, none under way, none of them phase 3. Galantamine · Alzheimer Disease.

Enrollment
28th of 28
1 · median 248
Started
2011
with 2 others
Phase 4
8 of 30
none open now
Registered
28th of 30
by date
Lead sponsor
1 of 30
Janssen-Cilag, S.A.

Among the 30 studies testing galantamine in Alzheimer Disease, this one is the 28th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2011, is one of 8 in phase 4, and was the 28th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

None of the 30 studies testing galantamine in Alzheimer Disease is open now. The open studies under Alzheimer Disease, anywhere →

About galantamine

Galantamine: first FDA approval 2001 (RAZADYNE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing galantamine in Alzheimer Disease as a file.
02

Study summary

The purpose of this study is to assess the modulating effect of galantamine on circadian rhythm in patients with moderate Alzheimer's disease.

Read the detailed description

This is a pilot, single-group, interventional, prospective study including patients with moderate Alzheimer's disease, treated with galantamine. Galantamine is thought to benefit the cognitive functioning of those with Alzheimer's disease. The starting treatment dose is 8 mg/day for 4 weeks. The initial maintenance dose of galantamine is 16 mg/day. Patients should be maintained on 16 mg/day for 4 weeks. An increase to the maintenance dose of 24 mg/day should be considered on an individual basis after the appropriate assessment including evaluation of clinical benefit and tolerability. For individual patients not showing an increased response or not tolerating 24 mg/day, a dose reduction to 16 mg/day should be considered. The primary objective is the assessment of the modulating effect of galantamine (Reminyl PRC) on circadian rhythm (wake/sleep) in patients with moderate Alzheimer's disease. The secondary objective is to assess the perception of the physicians, caregivers and patients themselves on sleep-wake disorders in patients with moderate Alzheimer's disease before and after treatment with galantamine. Sleep disturbances will be assessed by two actigraphy measures: one, before starting treatment, and the other, 12 weeks after the first actigraphic measure. The primary endpoint is the day/night ratio measured by the actigraphy before and after treatment with galantamine in patients with moderate Alzheimer-type dementia. Concerning the Efficacy Measures, the Actigraphy will be used as a method to assess the modulating effect of galantamine on circadian rate. The impact of this modulating effect on the caregivers, patients themselves and physicians will be assessed by three questionnaires: the Zarit Caregiver Burden Interview (ZBI), the Pittsburgh Sleep Quality Index (PSQI) and the Clinical Global Impression (CGI), respectively. Patient safety will be monitored. It is estimated that the study period will range from September 2010 to the second quarter of 2011.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer Disease
  • Dementia
  • Sleep Disorders
  • Galantamine
  • Reminyl
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Alzheimer-type dementia according to the definition of the , Fourth Edition (DSM IV-TR) and a diagnosis of possible or probable Alzheimer-type dementia, according to NINCDS-ADRDA classification (American Psychiatric Association, 2000
  • McKhann, G. et al, 1984)
  • should have moderate dementia, evidenced by a Mini-Mental Status examination () score between 12 and 20, including these limits
  • At inclusion, a recent CT or MRI must be available
  • Physical examination and the (ECG) performed at the screening visit must be normal or consistent with the underlying illness in the study population
  • History of sleep behavior changes (eg: insomnia, daytime sleepiness, changes in sleep/wakefulness cycle) 2 or more weeks before, reported by the caregiver
  • Patients should have a caregiver sufficiently informed of their condition and, if possible, living with them
  • Patients (or their legally-acceptable representatives) must have signed an document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • History of other neurodegenerative disorders, such as Parkinson's disease, Pick disease or Huntington's chorea, Down syndrome, Creutzfeldt-Jakob disease (patients with mild extrapyramidal signs for which no treatment is required are not excluded from the trial)
  • cardiovascular disease expected to limit the ability of the patient to participate and complete the study
  • Any history of epilepsy or seizures (except for febrile seizures in childhood)
  • Clinically significant psychiatric condition, according to the criteria, particularly major depression or schizophrenia currently
  • Active peptic ulcer (treatment of the disease started \< 3 months or treatment is not successful
  • Clinically significant liver, renal, pulmonary, metabolic, or endocrine disorders
  • Clinically significant urinary flow obstruction
  • History of or suspected alcoholism or drug abuse in accordance to the DSM-IV criteria, in the past year, or previous history of prolonged abuse
  • Previous therapy with memantine or an acetylcholinesterase inhibitor (including galantamine)
  • Patients receiving antipsychotics, hypnotic or sedative agents (those patients who need this kind of medication during the study would be withdrawn from the study and replaced)
  • Bedridden patients
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Galantamine

    Drug: Galantamine

Interventions

  • Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Sleep/Wake Patterns as Measured by Actigraph at 12 Weeks

    Actigraph is a small portable device that is worn on the wrist of the non-dominant arm to measure body movement during long time periods. It creates a pattern based on activity that is useful in assessing sleep-wake cycles across many consecutive days and nights. It is useful for assessing sleep phase disorders.

    Time frame: Baseline and 12 weeks

07

Results

Posted Aug 14, 2012

Participant flow

Participant flow — Overall Study
MilestoneGalantamine
Started1
Completed0
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange From Baseline in Sleep/Wake Patterns as Measured by Actigraph at 12 Weeks

Actigraph is a small portable device that is worn on the wrist of the non-dominant arm to measure body movement during long time periods. It creates a pattern based on activity that is useful in assessing sleep-wake cycles across many consecutive days and nights. It is useful for assessing sleep phase disorders.

Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Galantamine—0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Galantamine
<=18 years0
Between 18 and 65 years0
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Galantamine
Female1
Male0
08

Study locations

1 site
  • Barcelona, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2010
First posted
Aug 13, 2010
Start
May 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Aug 14, 2012
Last update
May 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01181921
Responsible party
Sponsor
First posted
Aug 13, 2010
Start date
May 2011
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Aug 14, 2012
Last update
May 1, 2014

Study contacts

Janssen-Cilag S.A. (formerly Janssen Sp) Clinical Trial
study director · Janssen-Cilag, S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Galantamine

Start the discussion